Nitric Oxide and Tumors: From Small-Molecule Donor to Combination Therapy

ACS Biomater Sci Eng. 2023 Jan 9;9(1):139-152. doi: 10.1021/acsbiomaterials.2c01247. Epub 2022 Dec 28.

Abstract

As an important endogenous signaling molecule, nitric oxide (NO) is involved in various physiological and pathological activities in living organisms. It is proved that NO plays a critical role in tumor therapy, while the extremely short half-life and nonspecific distribution of NO greatly limit its further clinical applications. Thus, the past few decades have witnessed the progress made in conquering these shortcomings, including developing innovative NO donors, especially smart and multimodal nanoplatforms. These platforms can precisely control the spatiotemporal distribution of therapeutic agents in the organism, which make big differences in tumor treatment. Here current NO therapeutic mechanisms for cancer, NO donors from small molecules to smart-responsive nanodrug delivery platforms, and NO-based combination therapy are comprehensively reviewed, emphasizing outstanding breakthroughs in these fields and hoping to bring new insights into NO-based tumor treatments.

Keywords: combined therapy; intelligent response; nanodrug delivery system; nitric oxide; tumor therapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Carriers / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Nitric Oxide Donors / therapeutic use
  • Nitric Oxide* / therapeutic use

Substances

  • Nitric Oxide
  • Nitric Oxide Donors
  • Drug Carriers